Grant ID DP200034
Awarded On May 20, 2020
Title CARGo: a CAR-T cell program targeting HLA-G - a novel immune checkpoint and tumor specific antigen for advanced clear cell renal and ovarian carcinomas
Program Product Development Research
Award Mechanism Company Relocation
Institution/Organization Invectys USA Inc
Principal Investigator/Program Director Simon Wain-Hobson
Cancer Sites Kidney and Renal Pelvis, Ovary
Contracted Amount $14,196,990*

*Pending contract negotiation

Lay Summary

Invectys S.A. is a French biopharmaceutical company developing innovative anti-cancer products in immunotherapy based on leading technology from the Institut Pasteur in Paris. The Company is applying for a CPRIT relocation grant to advance its novel CAR-T platform to be able to conduct early stage clinical studies in Texas.

Invectys research is focused on the HLA-G molecule, a powerful modulator of the human immune system. It is the only cancer immunotherapy company focused on HLA-G: a highly significant and novel approach. HLA-G protects the fetus from the mother's immune system. However, in cancer tumors, cells are selected that express HLA-G to protect the tumor from attacks of the immune...

Read More